GU Cancers Symposium 2012

GU Cancers Symposium 2012

February 2 - 4, 2012
San Francisco Marriott Marquis
San Francisco, CA USA
Prostate cancer session highlights sponsored by Bristol-Myers Squibb

GU Cancers Symposium 2012 - Novel Mechanisms and Therapies in Multidisciplinary Management - Program Announcement

SAN FRANCISCO, CA USA (UroToday.com) - Join us for the 2012 Genitourinary Cancers Symposium

GU Cancers Symposium 2012 - Active surveillance vs. watchful waiting for localized prostate cancer

SAN FRANCISCO, CA, USA (UroToday.com) - In a recent issue of the ASCO Post, a NIH panel of experts released a document to guide physicians in their evaluation of active surveillance (AS) of localized prostate cancer.

GU Cancers Symposium 2012 - mCRPC opportunities for the urologist and radiation oncologist: An interview with Adam M. Kibel, Chairman, GU Cancers Symposium - Session Highlights

SAN FRANCISCO, CA, USA (UroToday.com) - The 2012 GU Cancers Symposium sponsored by ASCO, ASTRO and SUO had a record setting attendance with a third of the audience being urologists and nearly 20% radiation oncologists.

GU Cancers Symposium 2012 - Prostate cancer: Take home message - Session Highlights

SAN FRANCISCO, CA, USA (UroToday.com) -

GU Cancers Symposium 2012 - Radium-223 chloride impact on skeletal-related events in patients with castration-resistant prostate cancer (CRPC) with bone metastases: A phase III randomized trial (ALSYMPCA) - Session Highlights

SAN FRANCISCO, CA, USA (UroToday.com) - Results from ALSYMPCA trial reveal that radium-223 chloride, a local-acting calcium mimetic, significantly prolongs both overall survival and the time to the first skeletal-related event (SRE), compared with placebo, in patients with castration-resistant prostate cancer (CRPC) and bone metastases.

GU Cancers Symposium 2012 - Empiric antibiotics for an elevated PSA: A randomized, prospective multiinstitutional trial - Session Highlights

SAN FRANCISCO, CA, USA (UroToday.com) - Researchers from six medical centers investigated the empiric use of the antibiotic (ciprofloxacin 500 mg given twice daily) to treat 77 asymptomatic males with newly elevated PSA (>2.5 ng/ml) undergoing their first prostate biopsy.

GU Cancers Symposium 2012 - Validation of a cell-cycle progression (CCP) gene panel to improve risk stratification in a contemporary prostatectomy cohort - Session Highlights

SAN FRANCISCO, CA, USA (UroToday.com) - Researchers at UCSF are investigating novel biomarkers to help predict tumor behavior with greater accuracy.

GU Cancers Symposium 2012 - A randomized phase II study of OGX-427 + prednisone vs. prednisone alone in patients with chemotherapy-naïve metastatic castration resistant prostate cancer - Session Highlights

SAN FRANCISCO, CA, USA (UroToday.com) - OGX-427 is a second generation 2’-O-methoxyethyl phosphorothioate (2’-MOE) antisense oligonucleotide.

GU Cancers Symposium 2012 - Hypofractionation for prostate cancer: Is less better? - Session Highlights

SAN FRANCISCO, CA, USA (UroToday.com) - Dr. W. Robert Lee expressed the potential advantages of a hypofractionation schedule (using fewer fractions with larger doses per fraction)

GU Cancers Symposium 2012 - Approved agents and related trials - Session Highlights

SAN FRANCISCO, CA, USA (UroToday.com) - Dr. Gary MacVicar challenged the GU Symposium audience to effectively sequence, combine therapies, and target treatments to men with metastatic CRPC.